Prognostic Factors for Patients with Small-Cell Lung Cancer Treated with Chemoimmunotherapy: A Retrospective Multicenter Study.

IF 2.8 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2024-10-23 DOI:10.3390/curroncol31110482

Takashi Hatori, Takeshi Numata, Toshihiro Shiozawa, Manato Taguchi, Hirofumi Sakurai, Tomohiro Tamura, Jun Kanazawa, Hiroaki Tachi, Kyoko Kondo, Kunihiko Miyazaki, Norihiro Kikuchi, Koichi Kurishima, Hiroaki Satoh, Nobuyuki Hizawa

{"title":"Prognostic Factors for Patients with Small-Cell Lung Cancer Treated with Chemoimmunotherapy: A Retrospective Multicenter Study.","authors":"Takashi Hatori, Takeshi Numata, Toshihiro Shiozawa, Manato Taguchi, Hirofumi Sakurai, Tomohiro Tamura, Jun Kanazawa, Hiroaki Tachi, Kyoko Kondo, Kunihiko Miyazaki, Norihiro Kikuchi, Koichi Kurishima, Hiroaki Satoh, Nobuyuki Hizawa","doi":"10.3390/curroncol31110482","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to investigate prognostic factors for predicting the survival of patients with extensive-disease-stage small-cell lung cancer treated with chemoimmunotherapy.Methods: Patients were classified according to overall survival (OS): favorable corresponded to an OS ≥ 24 months, moderate corresponded to an OS of 6-24 months, and poor corresponded to an OS < 6 months. Multivariate Cox regression analyses were used to evaluate prognostic factors.Results: Of 130 patients, the proportions of performance status decline and liver metastasis were significantly higher in the poor-prognosis group. With regard to the laboratory findings, neutrophil/lymphocyte ratios and albumin levels differed significantly among the groups. Multivariate analysis showed that the independent prognostic factors for OS were liver metastasis and decreased albumin levels (<3.5 mg/dL). After classifying the patients into three groups according to the quantities of these prognostic factors, the OS differed significantly among the groups (18.3 vs. 13.5 vs. 3.8 months; p < 0.001). The incidence of immune-related adverse events (irAEs) was higher in patients without these prognostic factors than in those with both (36% vs. 5%; p = 0.01).Conclusion: Liver metastasis and decreased albumin levels are independent unfavorable prognostic factors. Patients with both prognostic factors showed unfavorable OS; however, patients without these factors may have a favorable prognosis but be at greater risk of irAEs.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6502-6511"},"PeriodicalIF":2.8000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592429/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31110482","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to investigate prognostic factors for predicting the survival of patients with extensive-disease-stage small-cell lung cancer treated with chemoimmunotherapy.

Methods: Patients were classified according to overall survival (OS): favorable corresponded to an OS ≥ 24 months, moderate corresponded to an OS of 6-24 months, and poor corresponded to an OS < 6 months. Multivariate Cox regression analyses were used to evaluate prognostic factors.

Results: Of 130 patients, the proportions of performance status decline and liver metastasis were significantly higher in the poor-prognosis group. With regard to the laboratory findings, neutrophil/lymphocyte ratios and albumin levels differed significantly among the groups. Multivariate analysis showed that the independent prognostic factors for OS were liver metastasis and decreased albumin levels (<3.5 mg/dL). After classifying the patients into three groups according to the quantities of these prognostic factors, the OS differed significantly among the groups (18.3 vs. 13.5 vs. 3.8 months; p < 0.001). The incidence of immune-related adverse events (irAEs) was higher in patients without these prognostic factors than in those with both (36% vs. 5%; p = 0.01).

Conclusion: Liver metastasis and decreased albumin levels are independent unfavorable prognostic factors. Patients with both prognostic factors showed unfavorable OS; however, patients without these factors may have a favorable prognosis but be at greater risk of irAEs.

查看原文本刊更多论文

化疗免疫疗法小细胞肺癌患者的预后因素：一项回顾性多中心研究

背景：本研究旨在探讨化疗免疫治疗广泛病变期小细胞肺癌患者的预后因素：本研究旨在探讨预测化疗免疫疗法广泛病变期小细胞肺癌患者生存期的预后因素：根据总生存期（OS）对患者进行分类：OS≥24个月为良好，6-24个月为中等，小于6个月为不良。多变量Cox回归分析用于评估预后因素：结果：在130名患者中，预后不良组中表现状态下降和肝转移的比例明显较高。在实验室检查结果方面，中性粒细胞/淋巴细胞比率和白蛋白水平在各组间存在显著差异。多变量分析显示，肝转移和白蛋白水平下降是影响OS的独立预后因素（P < 0.001）。无上述预后因素的患者免疫相关不良事件（irAEs）发生率高于同时存在上述预后因素的患者（36% vs. 5%；P = 0.01）：结论：肝转移和白蛋白水平下降是独立的不利预后因素。结论：肝转移和白蛋白水平下降是独立的不利预后因素，同时具有这两个预后因素的患者显示出不利的OS；然而，不具有这些因素的患者可能预后良好，但发生虹膜AEs的风险更大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.